ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: May 14, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | May 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
ANI Pharma dropped an 8-K detailing financials and operations. Check it out.
AI Summary
ANI Pharmaceuticals, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, previously known as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc., is incorporated in Delaware and headquartered in Baudette, Minnesota.
Why It Matters
This 8-K filing provides crucial updates on ANI Pharmaceuticals' financial performance and operational status, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial information and does not indicate any unusual or high-risk events.
Key Players & Entities
- ANI Pharmaceuticals, Inc. (company) — Registrant
- BioSante Pharmaceuticals Inc. (company) — Former company name
- Ben Abraham Technologies Inc. (company) — Former company name
- May 14, 2024 (date) — Date of report
- 210 Main Street West, Baudette, Minnesota 56623 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on ANI Pharmaceuticals, Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 14, 2024.
What are the previous names of ANI Pharmaceuticals, Inc.?
ANI Pharmaceuticals, Inc. was formerly known as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc.
Where is ANI Pharmaceuticals, Inc. headquartered?
ANI Pharmaceuticals, Inc. is headquartered at 210 Main Street West, Baudette, Minnesota 56623.
What is the state of incorporation for ANI Pharmaceuticals, Inc.?
ANI Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-14 16:11:27
Filing Documents
- ani-20240514.htm (8-K) — 29KB
- exhibit991investordeckma.htm (EX-99.1) — 15KB
- exhibit991investordeckma001.jpg (GRAPHIC) — 63KB
- exhibit991investordeckma002.jpg (GRAPHIC) — 313KB
- exhibit991investordeckma003.jpg (GRAPHIC) — 123KB
- exhibit991investordeckma004.jpg (GRAPHIC) — 106KB
- exhibit991investordeckma005.jpg (GRAPHIC) — 124KB
- exhibit991investordeckma006.jpg (GRAPHIC) — 156KB
- exhibit991investordeckma007.jpg (GRAPHIC) — 113KB
- exhibit991investordeckma008.jpg (GRAPHIC) — 63KB
- 0001023024-24-000059.txt ( ) — 1633KB
- ani-20240514.xsd (EX-101.SCH) — 2KB
- ani-20240514_lab.xml (EX-101.LAB) — 21KB
- ani-20240514_pre.xml (EX-101.PRE) — 12KB
- ani-20240514_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On May 14, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., participated in a panel discussion at the Capital One Securities 1st Annual Biotech/Biopharma Disruptors Event in New York City. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
01
Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated May 1 4, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 14, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer